To investigate the possibility that melanoma cells modulate HB-EGF and/or EGFR expression to evade drug-induced cell death, we examined the expression of HB-EGF and EGFR after treatment with the anti-myelosuppressive drugs doxorubicin (DOX) and bortezomib (BTZ) [26,37]. Here, HBEGF is linked to melanoma.